pI: 9.416 |
Length (AA): 369 |
MW (Da): 44528 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 1
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 13 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
90 | 189 | 2ctw (A) | 3 | 109 | 28.00 | 0 | 1 | 0.66 | -0.41 |
98 | 201 | 1gh6 (A) | 7 | 113 | 20.00 | 0 | 0.68 | 0.54 | -0.17 |
101 | 164 | 2ctp (A) | 6 | 69 | 48.00 | 0.0000000000047 | 1 | 1.02 | -2.07 |
4 | 41 | 4gco (A) | 139 | 176 | 26.00 | 0.48 | 0.93 | 0.529681 | -0.87 |
6 | 76 | 4gcn (A) | 3 | 73 | 17.00 | 0.97 | 0.74 | 0.531112 | -1.08 |
9 | 158 | 2y4t (A) | 269 | 453 | 22.00 | 0.011 | 1 | 0.483604 | 0.01 |
102 | 171 | 3ucs (C) | 4 | 73 | 36.00 | 0.034 | 1 | 0.869802 | -2.32 |
102 | 201 | 4j80 (A) | 5 | 104 | 35.00 | 0.000031 | 1 | 0.845103 | -1.36 |
103 | 198 | 4j7z (A) | 6 | 97 | 47.00 | 0.00000000012 | 1 | 0.736163 | -1.24 |
4 | 41 | 4gco (A) | 139 | 176 | 26.00 | 0.14 | 0.92 | 0.522081 | -0.82 |
8 | 68 | 3lca (A) | 127 | 187 | 16.00 | 0.7 | 0.27 | 0.488412 | -1.51 |
101 | 165 | 2ctq (A) | 19 | 84 | 40.00 | 0.00058 | 1 | 0.856752 | -1.99 |
102 | 233 | 3apq (A) | 34 | 162 | 26.00 | 0.095 | 1 | 0.673024 | -0.44 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Sporozoite. | Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 16 hs, intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, sporozoite, early ring, Ring. | Otto TD PlasmoDB Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | early schizont, early trophozoite, late trophozoite, Oocyst, Male Gametocyte. | PlasmoDB Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Female Gametocyte. | Lasonder E |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Ortholog group members (OG5_127638)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G49060 | chaperone protein dnaJ 49 |
Arabidopsis thaliana | AT5G05750 | DNAJ heat shock N-terminal domain-containing protein |
Arabidopsis thaliana | AT3G57340 | DnaJ/Hsp40 domain-containing protein |
Babesia bovis | BBOV_IV011520 | DnaJ domain containing protein |
Brugia malayi | Bm1_26280 | DnaJ domain containing protein |
Candida albicans | CaO19.7175 | DnaJ-like protein similar to S. cerevisiae HLJ1 (YMR161W) tail-anchored ER membrane protein |
Candida albicans | CaO19_7175 | hypothetical protein |
Caenorhabditis elegans | CELE_B0035.14 | Protein DNJ-1, isoform B |
Cryptosporidium hominis | Chro.50028 | CG3061-PA |
Cryptosporidium parvum | cgd5_3430 | DNAj protein with possible transmembrane domain within C-terminal region |
Dictyostelium discoideum | DDB_G0281775 | hypothetical protein |
Drosophila melanogaster | Dmel_CG3061 | CG3061 gene product from transcript CG3061-RA |
Echinococcus granulosus | EgrG_000673700 | DnaJ protein subfamily B 2 |
Echinococcus multilocularis | EmuJ_000673700 | DnaJ protein subfamily B 2 |
Homo sapiens | ENSG00000164031 | DnaJ (Hsp40) homolog, subfamily B, member 14 |
Homo sapiens | ENSG00000148719 | DnaJ (Hsp40) homolog, subfamily B, member 12 |
Leishmania braziliensis | LbrM.35.2340 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_362230.1 | chaperone protein DnaJ, putative |
Leishmania infantum | LinJ.36.2230 | hypothetical protein, conserved |
Leishmania major | LmjF.36.2110 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.36.2110 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_13030 | DnaJ domain-containing protein |
Loa Loa (eye worm) | LOAG_14276 | DnaJ domain-containing protein |
Mus musculus | ENSMUSG00000020109 | DnaJ (Hsp40) homolog, subfamily B, member 12 |
Mus musculus | 70604 | DnaJ (Hsp40) homolog, subfamily B, member 14 |
Neospora caninum | NCLIV_026920 | hypothetical protein |
Oryza sativa | 4324566 | Os01g0556400 |
Oryza sativa | 4338551 | Os05g0364500 |
Onchocerca volvulus | OVOC5639 |
|
Plasmodium berghei | PBANKA_0911800 | DnaJ protein, putative |
Plasmodium falciparum | PF3D7_1136800 | DnaJ protein, putative |
Plasmodium knowlesi | PKNH_0935000 | DnaJ protein, putative |
Plasmodium vivax | PVX_092455 | DnaJ domain containing protein |
Plasmodium yoelii | PY05753 | DNAJ-like protein, putative |
Saccharomyces cerevisiae | YMR161W | Hlj1p |
Schistosoma japonicum | Sjp_0217370 | ko:K09518 DnaJ homolog, subfamily B, member 12, putative |
Schistosoma mansoni | Smp_132870 | DNAj homolog subfamily B member |
Schmidtea mediterranea | mk4.007709.01 | |
Schmidtea mediterranea | mk4.005228.00 | |
Trypanosoma brucei gambiense | Tbg972.10.8080 | chaperone protein DNAj, putative |
Trypanosoma brucei | Tb927.10.6610 | chaperone protein DnaJ, putative |
Trypanosoma congolense | TcIL3000_10_5680 | chaperone protein DnaJ, putative |
Trypanosoma cruzi | TcCLB.510187.330 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_259980 | DnaJ domain-containing protein |
Theileria parva | TP01_1152 | hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.6610 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.6610 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.6610 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.10.6610 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_0911800 | Plasmodium berghei | Essential | plasmo |
TGME49_259980 | Toxoplasma gondii | Probably essential | sidik |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.